The growing use of weight-loss medications, particularly GLP-1 drugs, is reshaping how people manage their health and approach weight reduction. Recent survey data reveals that in the United States, about one in eight adults were actively using these medications during the latter half of 2025. In comparison, usage rates are lower in other countries, such as Britain, where only 4 percent of adults reported taking weight-loss drugs last year.
Experts agree that GLP-1 medications are effective at helping users lose weight while on treatment, with Americans seeing some of the most dramatic results due to early adoption. However, these individual achievements have not yet translated into significant national decreases in obesity rates. In England, no meaningful reduction has been noted as of 2024, while in the US, the data is mixed depending on the sources and timelines used. Some reports indicate obesity levels declined since 2022, others suggest they have plateaued, and a few even argue they may have peaked earlier.
One reason the national impact is limited may be the relatively modest adoption of these drugs so far, along with strict prescription rules in some countries. Many users also stop taking the medication relatively quickly; studies show that only about 65 percent of Americans prescribed GLP-1 drugs between 2016 and 2023 remained on the treatment for at least three months.
Researchers are also examining how the rise in weight-loss drug use affects healthcare costs and food spending. The hope was that reducing obesity would bring lower medical expenses by decreasing serious health risks like heart attacks. However, studies have so far found no evidence that GLP-1 drugs reduce overall healthcare costs. Instead, medical spending tends to rise due to additional monitoring and management of drug side effects. With only a few years of data on newer medications, experts remain cautious about whether future results might differ.
On the consumer side, weight-loss drug users are buying less food, especially highly processed items. British users, for instance, spend about 2 percent less on groceries than their peers. While these changes are small on a national scale, they may worry individual businesses and food producers, especially as drug prices fall and usage increases. Interestingly, users on GLP-1 drugs are willing to pay more for protein-rich foods. When people stop taking the medication, their desire for sweet treats, like chocolate and candy, often rebounds, sometimes becoming even stronger than before. These trends suggest that the effects of weight-loss drugs extend beyond personal health, influencing spending habits and the wider food industry.
